SCHEMBL725613

SCHEMBL725613

CCCCCCCCCCCCCC(=O)CC(C[N+](C)(C)C)C(=O)CCCCCCCCCCCCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.47
MAPT P10636 4/20 0.47
MEN1 O00255 3/20 0.47
GMNN O75496 3/20 0.47
LMNA P02545 3/20 0.47
KMT2A Q03164 3/20 0.47
NPSR1 Q6W5P4 3/20 0.47
TP53 P04637 3/20 0.47
TSHR P16473 3/20 0.47
CYP1A2 P05177 2/20 0.47
HSP90AA1 P07900 2/20 0.47
BLM P54132 2/20 0.47
NR1H4 Q96RI1 2/20 0.47
CYP2C9 P11712 2/20 0.47
HIF1A Q16665 2/20 0.47
CES2 O00748 1/20 0.46
SLC25A20 O43772 3/20 0.46
CYP2D6 P10635 2/20 0.46
GLA P06280 1/20 0.46
PMP22 Q01453 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL625634 1.00 MAPK1 (0.47) MAPK1MAPTMEN1GMNNLMNA
SCHEMBL626223 1.00 MAPK1 (0.47) MAPK1MAPTMEN1GMNNLMNA
Hydrochloric Acid SCHEMBL17241611 0.98 MAPK1 (0.48) MAPK1MAPTMEN1GMNNLMNA
Hydrochloric Acid SCHEMBL1773167 0.98 MAPK1 (0.48) MAPK1MAPTMEN1GMNNLMNA
SCHEMBL29077348 0.91 SLC6A5 (0.52) MAPTMEN1GMNNLMNAKMT2A
SCHEMBL533830 0.91 SLC6A5 (0.52) MAPTMEN1GMNNLMNAKMT2A
SCHEMBL533829 0.91 SLC6A5 (0.52) MAPTMEN1GMNNLMNAKMT2A
Hydrochloric Acid SCHEMBL20258167 0.90 SLC6A5 (0.51) MAPTMEN1GMNNLMNAKMT2A
Hydrochloric Acid SCHEMBL1773161 0.90 SLC6A5 (0.51) MAPTMEN1GMNNLMNAKMT2A
Hydrochloric Acid SCHEMBL28566602 0.90 SLC6A5 (0.51) MAPTMEN1GMNNLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 653 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118813629-A MRNA for expressing aquaporin AQP3 and application thereof 北京键凯科技股份有限公司 2024-10-22 CN claimed
CN-118767154-A Multi-arm polyethylene glycol drug conjugate and application thereof 北京键凯科技股份有限公司 2024-10-15 CN claimed
CN-118613491-A SARS-COV-2 RNA vaccine compositions and methods of use 赫德特生物公司 2024-09-06 CN claimed
CN-118555964-A Cancer treatment composition and use thereof 赫德特生物公司 2024-08-27 CN claimed
US-20240216274-A1 DRIED NANOPARTICLE COMPOSITIONS HDT BIO CORP. 2024-07-04 US claimed
WO-2024144348-A1 VACCINE COMPOSITION COMPRISING IONIC COMPLEX OF CATIONIC MOLECULAR TRANSPORTER AND MRNA 주식회사 바이오파마 2024-07-04 WO claimed
CN-118284410-A Dried nanoparticle compositions 赫德特生物公司 2024-07-02 CN claimed
US-20240207186-A1 NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR LOADING RNA LAWRENCE LIVERMORE NATIONAL SECURITY, LLC 2024-06-27 US claimed
US-20240197865-A1 COMPOSITIONS AND METHODS FOR PREVENTING RSV AND PIV3 INFECTIONS UNIVERSITY OF SASKATCHEWAN (CA) 2024-06-20 US claimed
US-20240165222-A1 VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 EYEGENE INC. (KR) 2024-05-23 US claimed
WO-2011158237-A1 PHOSPHATIDYLCHOLINE LIPID LIPOSOMES AS BOUNDARY LUBRICANTS IN AQUEOUS MEDIA YEDA RESEARCH AND DEVELOPMENT CO. LTD., (IL) 2011-12-22 WO claimed
US-20110287087-A1 MODIFIED CATIONIC LIPOSOME ADJUVANS STATENS SERUM INSTITUT (DK) 2011-11-24 US claimed
WO-2011098578-A2 LIPOSOME SYSTEM FOR OCULAR ADMINISTRATION BIONEER A/S (DK) 2011-08-18 WO claimed
US-20080118489-A1 Charge-Modified Lysozyme Antimicrobial Compositions, Surfactants, and Methods for Infections and Cystic Fibrosis THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2008-05-22 US claimed
US-20070014842-A1 Pharmaceutical liposomal compositions ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) 2007-01-18 US claimed
US-20070014841-A1 Pharmaceutical compositions ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) 2007-01-18 US claimed
US-20020102297-A1 Macromolecule-lipid complexes and methods for making and using THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-08-01 US claimed
EP-1225916-A1 COMPOSITIONS AND METHODS FOR CONTROLLED-RELEASE DELIVERY AND INCREASED POTENCY OF PHARMACEUTICALS VIA HYDROPHOBIC ION-PAIRING University Technology Corporation (US) 2002-07-31 EP claimed
WO-2001032218-A1 COMPOSITIONS AND METHODS FOR CONTROLLED-RELEASE DELIVERY AND INCREASED POTENCY OF PHARMACEUTICALS VIA HYDROPHOBIC ION-PAIRING UNIVERSITY TECHNOLOGY CORPORATION (US) 2001-05-10 WO claimed
WO-2000000033-A1 MACROMOLECULE-LIPID COMPLEXES AND METHODS FOR MAKING AND USING THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-01-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240197865-A1 COMPOSITIONS AND METHODS FOR PREVENTING RSV AND PIV3 INFECTIONS CCR3, CA13, MATR3 MAPK1 3563/4885MAPT 2989/4885MEN1 1612/4885
US-20240165222-A1 VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 ACE2, SARS1, RBM22 MAPK1 4479/4885MAPT 950/4885MEN1 4007/4885
US-20070014842-A1 Pharmaceutical liposomal compositions NGLY1, PHOSPHO1, LPXN MAPK1 4030/4885MAPT 2932/4885MEN1 8/4885
US-20240207186-A1 NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR LOADING RNA SARNP, SYNCRIP, AUP1 MAPK1 4666/4885MAPT 3603/4885MEN1 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.